{"url_path":"/sec/vtvt/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001193125-26-221971-index.html","accession_number":"0001193125-26-221971","cik":"0001641489","ticker":"VTVT","issuer_name":"vTv Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001193125-26-221971-index.html","primary_entity_key":"0001641489","primary_entity_name":"vTv Therapeutics Inc."},"word_count":86,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n \n\n \n(d)\n\nExhibits\n\n \n\nEXHIBIT\nNUMBER\n  \n\nDESCRIPTION\n\n5.1\n  \n[Opinion of Dechert LLP](d72453dex51.htm)\n\n23.1\n  \n[Consent of Dechert LLP (included in Exhibit 5.1)](d72453dex51.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n \n\n \n\n \nVTV THERAPEUTICS INC.\n\nDated: May 13, 2026\n \n\n \nBy:\n \n\n/s/ Michael Tung\n\n \n\n \n\n \nName: Michael Tung\n\n \n\n \n\n \nTitle: Chief Financial Officer"}